Alseres Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALSE research report →
About the company
Alseres Pharmaceuticals, Inc. focuses on creating both diagnostic and therapeutic solutions, with a primary emphasis on ailments affecting the central nervous system. Their flagship experimental compound is Altropane, a molecular imaging agent developed for identifying and diagnosing Parkinson's disease and dementia.
- CEO
- Peter G. Savas
- IPO
- 1994
- Employees
- 3
- HQ
- Auburndale, MA, US
Price Chart
- Market Cap
- $398.25K
- P/E
- -0.00
- P/S
- 0.84
- P/B
- -0.00
- EV/EBITDA
- -16.68
- Div Yield
- 0.00%
- Gross Margin
- 95.00%
- Op Margin
- -204.76%
- Net Margin
- -198.85%
- ROE
- 5.04%
- ROIC
- 76.81%
- Revenue
- $473.73K · -10.74%
- Net Income
- $-942,000 · 42.74%
- EPS
- $-153.67 · 42.78%
- Op Income
- $-970,000
- FCF YoY
- -77.11%
- 52W High
- $0.01
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- 0.21
- Avg Volume
- 0
Get TickerSpark's AI analysis on ALSE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 14, 09 | LANGER ROBERT | other | 25,000 |
| Jan 14, 09 | PRESTON JOHN T | other | 25,000 |
| Jan 14, 09 | SAVAS PETER G | other | 950,000 |
| Jan 14, 09 | SAVAS PETER G | sell | 400,000 |
| Jan 14, 09 | SAVAS PETER G | sell | 350,000 |
| Jan 14, 09 | SAVAS PETER G | sell | 200,000 |
| Jan 14, 09 | PYKETT MARK JEROME | other | 425,000 |
| Jan 14, 09 | PYKETT MARK JEROME | sell | 225,000 |
| Jan 14, 09 | PYKETT MARK JEROME | sell | 100,000 |
| Jan 14, 09 | PYKETT MARK JEROME | sell | 100,000 |
Our ALSE coverage
Recent articles, reports, and earnings notes.
No research on ALSE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALSE report →Similar companies
Peers in the same neighborhood.